Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Innovative Cellular Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. Each pending matter is associated with a distinct examiner and a distinct art unit, showing full dispersion across the supplied examination assignments.
TRAN, KHOA NHAT is the busiest examiner, with 1 pending matter. There is no recurring examiner concentration in the data. Counsel should manage the portfolio by application, preserve consistency where claim strategies overlap, and tailor responses to each separate technical examination setting.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18994494 | Recombinant Viral Particle for Gene and/or Cellular Therapy | TRAN, KHOA NHAT | — |
| 18571062 | Modified Cell Targeting Tumor ECM and Cellular Therapy thereof | PRIEST, JESSICA MARIE | — |
| 18260376 | CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996589 | Polyspecific Binding Molecules and their use in Cell Therapy | NICKOL, GARY B | 12d |
| 18994494 | Recombinant Viral Particle for Gene and/or Cellular Therapy | TRAN, KHOA NHAT | — |
| 18260376 | CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor | ROONEY, NORA MAUREEN | — |
| 18065301 | CELL THERAPY ACTIVATING LYMPHOCYTE IN TME | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1642 | 1 |
| 1641 | 1 |
| 1682 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18994494 | Recombinant Viral Particle for Gene and/or Cellular Therapy | TRAN, KHOA NHAT | 1632 | §102§103§112 | Non-Final OA | — | Pending | Jan 14, 2025 |
| 18571062 | Modified Cell Targeting Tumor ECM and Cellular Therapy thereof | PRIEST, JESSICA MARIE | 1642 | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18260376 | CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor | ROONEY, NORA MAUREEN | 1641 | §102§103 | Non-Final OA | — | Pending | Jul 05, 2023 |
| 18065301 | CELL THERAPY ACTIVATING LYMPHOCYTE IN TME | IVICH, FERNANDO NMN | 1682 | §102§112DP | Non-Final OA | — | Pending | Dec 13, 2022 |
| 17996589 | Polyspecific Binding Molecules and their use in Cell Therapy | NICKOL, GARY B | 1643 | §102 | Final Rejection | 12d | Pending | Oct 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovative Cellular Therapeutics Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Khoa Nhat Tran has the most, with 1 of Innovative Cellular Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
